(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 43.83% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Fennec Pharmaceuticals's revenue in 2026 is $44,642,000.On average, 8 Wall Street analysts forecast FENC's revenue for 2026 to be $2,705,784,345, with the lowest FENC revenue forecast at $2,046,343,141, and the highest FENC revenue forecast at $3,148,135,354. On average, 7 Wall Street analysts forecast FENC's revenue for 2027 to be $3,383,911,097, with the lowest FENC revenue forecast at $2,770,218,453, and the highest FENC revenue forecast at $4,148,398,169.
In 2028, FENC is forecast to generate $4,727,581,159 in revenue, with the lowest revenue forecast at $4,019,116,251 and the highest revenue forecast at $5,678,751,320.